ArticlePDF AvailableLiterature Review

Fmr1 KO Mice as a Possible Model of Autistic Features

Hindawi
The Scientific World Journal
Authors:

Abstract and Figures

Autism is a pervasive developmental disorder appearing before the age of 3, where communication and social interactions are impaired. It also entails stereotypic behavior or restricted interests. Although this disorder was first described in 1943, little is still known about its etiology and that of related developmental disorders. Work with human patients has provided many data on neuropathological and cognitive symptoms, but our understanding of the functional defects at the cellular level and how they come about remains sketchy. To improve this situation, autism research is in need of valid animal models. However, despite a strong hereditary component, attempts to identify genes have generally failed, suggesting that many different genes are involved. As a high proportion of patients suffering from the Fragile X Syndrome show many autistic symptoms, a mouse model of this disorder could potentially also serve as a model for autism. The Fmr1 KO mouse is a valid model of the Fragile X Syndrome and many data on behavioral and sensory-motor characteristics of this model have been gathered. We present here an assessment of autistic features in this candidate model. We conclude that Fmr1 KO mice display several autistic-like features, but more work is needed to validate this model.
Content may be subject to copyright.
Mini-Review Article
TheScientificWorldJOURNAL (2006) 6, 1164–1176
ISSN 1537-744X; DOI 10.1100/tsw.2006.220
*Corresponding author.
©2006 with author.
Published by TheScientificWorld, Ltd.; www.thescientificworld.com
1164
Fmr1 KO Mice as a Possible Model of
Autistic Features
Maude Bernardet* and Wim E. Crusio
Laboratoire de Neurosciences Cognitives, CNRS UMR 5106, Université de
Bordeaux I, Bat B2 - Avenue des Facultés, 33405 Talence Cedex, France
E-mail: m.bernardet@lnc.u-bordeaux1.fr
Received June 26, 2006; Revised September 1, 2006; Accepted September 6, 2006; Published September 20,2006
Autism is a pervasive developmental disorder appearing before the age of 3, where
communication and social interactions are impaired. It also entails stereotypic behavior
or restricted interests. Although this disorder was first described in 1943, little is still
known about its etiology and that of related developmental disorders. Work with human
patients has provided many data on neuropathological and cognitive symptoms, but our
understanding of the functional defects at the cellular level and how they come about
remains sketchy. To improve this situation, autism research is in need of valid animal
models. However, despite a strong hereditary component, attempts to identify genes
have generally failed, suggesting that many different genes are involved. As a high
proportion of patients suffering from the Fragile X Syndrome show many autistic
symptoms, a mouse model of this disorder could potentially also serve as a model for
autism. The Fmr1 KO mouse is a valid model of the Fragile X Syndrome and many data
on behavioral and sensory-motor characteristics of this model have been gathered. We
present here an assessment of autistic features in this candidate model. We conclude
that Fmr1 KO mice display several autistic-like features, but more work is needed to
validate this model.
KEYWORDS: animal model, autism, autistic-like traits, behavior, Fmr1 KO mice
AN OVERVIEW OF AUTISM
Autism is classified as a developmental pervasive disorder, the diagnosis of which is based on behavioral
symptoms and age of onset[1], with the earliest manifestations appearing before the age of 3. Essential
behavioral features of autistic disorder fall into three classes: abnormal or altered social interactions,
abnormal or altered social communication, and a restrained repertory of interests and activities.
Symptoms vary greatly between individuals[2,3,4]. Due to the variable clinical picture and the
accompanying blurring of diagnostic classes, estimations of the prevalence of autism vary widely, but
cluster around 6 births per 1000[5,6,7,8,9,10]. The syndrome is much more frequent in boys than girls,
with a ratio around 4:1.
Altered nonverbal social and communicative behaviors concern social gaze, facial mimics, body
postures, and gestures[1,3]. Autistic individuals often fail to establish relations with peers corresponding
to their levels of development. They may not spontaneously share their interests, pleasures, or
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1165
achievements with other people, and may lack social or emotional reciprocity[3,11,12]. Qualitative
communication alterations include a late display or complete lack of spoken language development
without compensation by nonverbal communication[1]. Even in subjects who master language
sufficiently, an inability to engage or sustain a conversation with a peer can be observed. Stereotyped and
repetitive use of language or idiosyncratic speech may occur. Lack of spontaneous playacting and of
social imitation play according to age of development also occurs frequently. The restrictive, repetitive,
and stereotyped character of behaviors, interests, and activities may be manifested by a preoccupation
circumscribed to one or more interest centers that is abnormal in its intensity or in its orientation. This
may also show as inflexible adhesion to habits, unspecific and nonfunctional rituals, or by stereotyped
motor mannerisms or persistent preoccupation for objects or parts of the body[3,13].
The core features of autism described above, defining the diagnosis of this disorder, are also
frequently associated with variable accompanying symptoms[1]. In most cases, mental retardation occurs,
the severity of which varies from light to profound (see [14] for a discussion). The profile of cognitive
capacities is usually heterogeneous and some particular skills may occur at a much higher level than most
other skills. Individuals with autism can display a variety of behavioral traits, such as hyperactivity,
attention deficit[15], impulsivity, self-injurious behavior, and, particularly in the youngest, anger
crises[16]. Mood or affect perturbations are frequent[17], as are disturbed sleep patterns[18,19]. The child
can lack fear in some dangerous situations, but show excessive fear in others. Responses to sensory
stimuli can be abnormal, e.g., a high threshold to pain, and hypersensitivity to noise and physical contact,
overreaction to lights or odors, or fascination for certain stimuli[20]. Convulsions occur in 5–38% of
cases, particularly before 5 years of age or in teenagers[21].
THE PUZZLE OF AUTISM: WHAT WE KNOW AND HOW WE KNOW IT
Since its description in 1943 by Kanner[3], there have been many efforts to link the behavioral features of
autism to underlying neural abnormalities. Psychiatric observations, combined with data from
experimental psychology, autopsies, and anatomic and functional magnetic resonance imaging, have
started to shed some light on the nature of this affliction. The anomalies observed in different brain
structures have led to different hypotheses implicating dysfunctions of the amygdala[11], orbitofrontal-
amygdala circuit[22], frontal-striatal system, and cerebellum[23]. In addition, alterations in various
neurotransmitter systems have been postulated[2].
Many structures were found to have an altered cytoarchitecture in autistic patients' brains: corpus
callosum[24,25,26], parts of the limbic system, cortex[27,28], cerebellum, and brainstem, but
observations were not always replicated. In the limbic system, the hippocampus, amygdala, entorhinal
cortex, subiculum, mammillary body, anterior cingulate cortex, and septum display small cell sizes and
increased cell packing densities at all ages (reviewed in [29,30]). Golgi analysis of CA1 and CA4
pyramidal neurons has shown decreased complexity and extent of dendritic arbors in these cells[31]. The
cerebellum is also affected. Decreases in numbers of Purkinje cells were systematically observed,
particularly in the inferior posterior hemisphere regions of the cerebellum[27,32,33,34].
Alterations may also differ as a function of age. Studies suggest that neurons in the vertical limb of
the diagonal band of Broca, in cerebellar nuclei, and in the inferior olive are abnormally large and
numerous in young individuals with autism, but are small, pale, and significantly reduced in number in
adult autistic individuals[27,29,30]. The events resulting in the observed decreased numbers of Purkinje
cells may occur before the connections between fibers of the olivary neurons and the Purkinje cells are
formed, and may account for a possible prenatal cause of autism (see [30]).
It was found that brains of children with autism are larger than those of age-matched controls, while
the brains of autistic adults tend to be lighter than controls[35]. Brain enlargement seems to be postnatal
as newborns show few or no differences with controls[36]. Many mechanisms have been hypothesized to
explain these observations, such as increase in neurogenesis, decrease in neuronal apoptosis, increase in
glial cell production, diminished synaptic pruning, or myelin abnormalities, but none has been confirmed.
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1166
It has been proposed that autistic disorders may have viral[37], autoimmune[38], teratogenic[39], or
genetic origins[40,41], none of these hypotheses being exclusive of the others. Congenital and neonatal
TORCH infections (acronym for Toxoplasmosis, Others [syphilis, varicella-zoster, and parvovirus B19],
Rubella, Cytomegalovirus, and Herpes) or autoimmune reactions to these pathogens have been associated
with autism[42,43]. Drug use during pregnancy has also been linked to increased frequency of autism. For
example, anticonvulsants, the mood stabilizer valproic acid, and antiemetic thalidomide have teratogenic
effects during early stages of intrauterine development. Minor malformations that occur frequently in
people with autism are known to arise in the same stages[39].
Support for a genetic basis of autism comes from a variety of sources, such as epidemiologic surveys,
family and twin studies, and linkage analyses[41,44,45]. Gross disruptions of chromosomal material
account for about 5% of cases of autism[46,47,48] and 5–12% of cases arise from disorders that affect the
brain and have a known genetic etiology, such as tuberous sclerosis and neurofibromatosis[49,50].
Samples of the remaining cases of idiopathic autism have been examined for heritability in family and
twin studies. Around 5% of siblings of autistic individuals will also develop the disorder; a rate that is 50
times higher than the 0.1% prevalence of autism in the general population[6,51]. In addition, 60–90% of
monozygotic twins are concordant for this disorder[52,53,54] and many family members of probands
appear to present various autistic traits, but in a milder form[55]. Genetic linkage studies have been
conducted on autistic probands and their families. Numerous loci have been found to be potentially linked
to the disorder, most of them being more or less specific for a given population[44]. Candidate genes
include alleles of genes implicated in development, e.g., Reelin and engrailed2, and others, such as the
SERT gene (serotonin transporter; [56,57]).
In conclusion, studies on humans have increased our understanding of autism and its developmental
origin is now generally accepted. Nevertheless, we still lack specific hypotheses to explain not only
autistic symptoms, but also their heterogeneity and their emergence during development. Human studies
are limited due to the scarcity of study material, personal and uncontrollable history of individuals,
variability and uncontrollability of genetic background, inability to isolate genetic and environmental
factors, indirect inference of brain operation within the limitations of current noninvasive methods to
investigate the brain, and the difficulty with which experimental results replicate. A valid animal model,
therefore, could clearly help to advance our knowledge significantly. A major challenge of any model of
autistic brain development is to take into account the neural substrates implicated and the variations that
can be observed between affected individuals.
FURTHER UNDERSTANDING: LOOKING FOR ANIMAL MODELS
It will be evident that no exact mouse equivalent can exist for such exquisitely human traits as are
affected in autism, or for any of the other common psychiatric disorders, for that matter. Moreover, some
human brain structures hardly have an equivalent or develop differently in mice. The prefrontal cortex,
for example, is thought to be involved in cognitive rigidity and is poorly developed in mice[58]. In order
to be useful, however, an animal model does not need to recapitulate a human disorder or syndrome
exactly. Indeed, it would appear that several of the intermediate traits (or endophenotypes) of autism can
be modeled in animals[59,60].
For an animal model to be considered relevant in psychiatric research, it should meet different criteria
of validity, such as construct, face, and predictive validity[61,62,63]. Thus, an acceptable animal model
for autism should reflect the developmental problems discussed above to satisfy the criterion of construct
validity. Face validity means that the model should display autistic-like behavioral traits resembling core
symptoms of autism concerning social relations, social communication, and restricted activities, and
should at least approximate most of the variable symptoms, such as anxiety, mental retardation,
clumsiness, aggression, hyperactivity, abnormal sensory responses, and stereotypies. Several behavioral
tasks have been designed for mice to assess autistic-like traits[64]. If indeed present, such behavioral
traits could be studied in the model after challenge with possible medications used in autistic patients to
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1167
improve particular symptoms. Predictive validity of the model would be established when these drugs
reduce or improve symptoms not only in the model, but in human patients, too.
Primates have been used to study social relations and social communication, but they have limitations
because of their high financial cost, long developmental time span, the fact that genetic manipulation is
impractical, and ethical considerations. Rodents do not suffer from these drawbacks. A limitation to the
use of rodent models for autism is the difficulty to model specific human features such as social gaze and
sharing of interests. Nevertheless, as we will see below, most behavioral features of autism can be
modeled in mice, which therefore could render valuable models for autism.
Belzung et al.[58] classified models for autism in four categories: (1) animals mutated for
neuropeptides implicated in social behavior and attachment (vasopressin, oxytocin, µ-opioid receptors),
(2) models of epigenetic factors implied in autism (developmental deficits in serotonin, fetal exposition to
anticonvulsants or thalidomide), (3) neonatal lesions of autism-associated structures, and (4) models of
genetic diseases associated with autism (e.g., Fragile X or Rett Syndrome and others). The problem with
the majority of these models is that they concern only some aspects of the etiology and not the whole
symptomatology, although the functional role of several structures has become better understood with
their help. Moreover, most of these models have up till now only been tested for a few autistic-like traits.
In what follows, we will review evidence that one of the models of Belzung's fourth category, the Fmr1
KO mouse, might also serve as a model for autism.
THE FRAGILE X SYNDROME
The FMR1 mutation underlying the Fragile X syndrome (FXS) is the most frequent cause of inherited
mental retardation and is interesting here because about 10–30% of these patients are also diagnosed with
autism[49,65,66,67]. FXS accounts for around 5% of the autistic population[49,68,69]. Many autistic
behavioral traits are common in FXS, even in patients that are not formally diagnosed with autism. FXS
also shares many of the variable features of autism such as hyperactivity[70], stereotypical behavior,
aggressiveness, anxiety (particularly due to social stress[70]), disturbed sleep patterns[71], high
prevalence of epilepsy[72], and impairment in sensorimotor gating[73]. Both disorders are developmental
and affect more boys than girls. It is interesting to note that although due to a single mutation, FXS
symptoms are very variable in quality and severity between individuals, another parallel with autism. For
all these reasons, autism researchers have become increasingly interested in FXS[74].
The FMRP protein, the product of the FMR1 gene, is expressed in brain tissue and in testes. In
neurons, it is localized either in the nucleus or cytoplasm[75,76,77], depending on the splicing[75]. It
complexes with other proteins[78] and is implicated in mRNA transport and translation
regulation[78,79,80,81]. Its own translation is thought to be dependent on synaptic activity. Although
much is known about its conformation, expression pattern, and localization, its role in mental retardation
remains to be elucidated.
A knock-out mutation has been induced in the mouse Fmr1 gene, which is 98% similar to its human
ortholog, FMR1[82]. FMRP expression was disrupted by introducing a neomycin cassette into exon 5 of
the gene[82]. Recently, Yan et al.[83] observed some residual Fmr1 RNA expression in these animals that
may be due to alternative splice variants. Nevertheless, Fmr1 KO mice display macroorchidism and
cognitive and other behavioral deficits comparable to those of human FXS patients[82]. In addition, the
abnormally long and thin dendritic spines characteristic of FXS patients are also found in young
KOs[84,85,86,87,88]. Fmr1 KO mice have been tested for numerous behavioral tasks relevant to FXS
and these animals have therefore been validated as a model for this disorder[89]. The relatively lighter
symptomatology of the disorder that has been observed in these mice for some features may be due to the
above-mentioned residual expression of splice variants of Fmr1 RNA[83].
The Fmr1 KO was produced in a 129 ES cell line and the resulting mutants were then recurrently
backcrossed to both C57BL/6J (B6) and FVB/N (FVB) animals. It appears that the mutation expresses
differently on these two backgrounds[90,91].
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1168
Fmr1 KO MICE: BEHAVIORAL CHECKUP RELEVANT TO AUTISTIC TRAITS
Fmr1 KO mice have been extensively studied for a large variety of behavioral and sensorimotor traits (see
Tables 1 and 2). Most studies aimed to validate these mice as a model for FXS and thus only relatively
few studies have assessed behavior relevant to the core symptoms of autism. An exception is abnormal
social behavior, which is also a prominent feature of FXS.
TABLE 1
Phenotypical Checkup of Fmr1 KO Mice: Behaviors Relevant to Core Symptoms of Autism
Test Background Result Ref.
Inappropriate social interactions
Mirrored chamber test B6 KO < WT for % time in the mirrored chamber [94]
Tube test of social dominance B6 KO < WT vs. unfamiliar WT the first time
KO = WT vs. unfamiliar WT the third day
KO = WT vs. familiar WT
[94]
Social interaction test B6 KO vs. WT:
Active social behavior: KO > WT
Passive social behavior: KO < WT
KO vs. KO, WT vs. WT:
Sniffing and receptive behavior: KO > WT
KO vs. C3H, WT vs. C3H: KO < WT
[94]
[95]
Crawley test B6 KO = WT [94]
Influence of cage familiarity on
response to unfamiliar social
partners
B6 In an unfamiliar cage: KO = WT; in a familiar
cage: KO < WT during the first 5 min, KO >
WT after 20 min
[94]
Perseverance
Water maze reversal learning:
Hidden-platform condition
Visible-platform condition
B6
B6
B6
B6
B6
B6
KO = WT
Escape latencies: KO > WT
Path length: KO > WT
Number of trials: KO > WT
Rate of learning:
KO = WT,
KO>WT
Escape latencies:
KO > WT
KO = WT
[97,98]
[82,89,96]
[96]
[98]
[96]
[89]
[96]
[82]
E-shaped water maze reversal
learning
B6 KO = WT [89]
Plus-shaped water maze
reversal learning
B6 Escape latencies: KO = WT, but rate of
learning: KO < WT
[98]
Although some core symptoms, such as sharing pleasures and interests with others, can hardly be
modeled in rodents, the inability to establish normal relations with peers and the lack of social reciprocity
can be assessed more easily. The mirrored chamber test, for instance, was developed by Seale and his
team[92] based on the notion that most animals react to their mirror image as if it was another animal[93].
The apparatus consists of a box, the interior of which is totally mirrored, laid out in the center of a dark
open field; the wall opposite the chamber is also mirrored. Fmr1 KO mice were found to spend less time
in the center mirrored chamber compared to total time spent in the mirrored alley (considered to be less
anxiogenic) and the mirrored chamber[94]. A tube test can be used to evaluate social dominance. If two
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1169
TABLE 2
Phenotypical Checkup of Fmr1 KO Mice: Behaviors Relevant to Variable Symptoms of Autism
Test Background Result Ref.
Anxiety
Elevated plus maze FVB
B6
FVBxB6
KO = WT
KO = WT
KO = WT
[100]
[91,107]
[107]
FVBxB6 KO less anxious than WT [83]
Thigmotaxis in open-field B6
FVBxB6
KO < WT
KO < WT
[94,101]
[83]
Boli in open-field
Light-dark exploration
B6
B6
KO < WT
Transitions between compartments: KO > WT
Time spent in both compartments: KO = WT
[94]
[82,101]
Corticosterone response to
acute stress
B6 Males:
Sham and 15 min: KO = WT
0 min: KO < WT
60 min: KO > WT
Females:
Sham, 0 and 60 min: KO = WT
15 min: KO < WT
[104]
B6 Males:
No stress, 30 min stress: KO = WT
2 h stress: KO > WT
[103]
Conditioned emotional response B6 KO = WT [98]
Learning and memory
Cross-shaped water maze
FVB
B6
Correct trials: KO < WT
Escape latencies: KO = WT
Correct trials:
KO < WT
KO = WT
[102]
[98]
[98]
[102]
Changing position of platform in
water maze
B6 KO = WT [97,98]
E-shaped water maze B6 KO = WT [89]
Morris water maze training:
Hidden-platform condition
Visible-platform condition
B6
FVBxB6
B6
FVB
B6
Escape latencies:
KO = WT
KO > WT
KO > WT the first four trials
Escape latencies: KO > WT
Rate of learning: KO = WT
Rate of learning: KO < WT
Escape latencies: KO = WT
[96,97,101]
[89]
[82]
[83]
[82,89,102]
[102]
[82,96]
Radial maze B6 Working memory: KO = WT [91]
FVBxB6 Working memory: KO < WT the first 6 days;
reference memory: KO < WT; strong choice
design: KO = WT
[83]
Barnes maze FVBxB6 KO = WT; during probe test: KO < WT [83]
Fear conditioning: context and
conditioned cue
FVB
B6
B6
KO = WT
KO = WT
KO < WT
[102]
[98,101,102]
[97]
Trace fear conditioning B6 KO < WT [100]
Conditioned eyelid blink reflex B6 KO < WT [109]
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1170
TABLE 2 (continued)
Test Background Result Ref.
Learning and memory (continued)
Passive avoidance (latency to
enter dark compartment)
B6
FVB
KO = WT
KO = WT
[82]
[108]
Lever press escape/avoidance
task
B6 KO < WT [113]
Instrumental conditioning B6 Conditioning learning : KO = WT [73]
Devaluation of reward and omission of lever
press : KO > WT
Olfactory learning and memory
tasks
FVBxB6 KO = WT [83]
Novel object task FVBxB6
FVB
KO = WT
KO < WT
[83]
[114]
Motor abilities
Rotarod motor coordination and
balance
B6 KO = WT [101]
Aggression
Neutral cage aggression test B6 KO = WT [91]
Hyperactivity
Open field activity B6
B6
FVBxB6
FVB
FVB
KO > WT
KO = WT
KO = WT
KO = WT
KO = WT before 18 min
KO > WT after 18 min
[91,94,101]
[107]
[107]
[100]
[108]
Activity cage FVB KO > WT [114]
Motor activity test B6 KO > WT [82]
Idiosyncratic responses to sensory stimuli
Auditory startle response B6 KO = WT, but increased response with
Fmr1gene containing YAC
[101]
B6 KO > WT at 70 and 80 dB; KO < WT at 120 dB [107]
B6 KO < WT at higher intensities, interaction
between genotype and intensity
[73]
FVB KO < WT [110]
FVB KO = WT under 110 dB; KO< WT from 110 dB
and above
[108]
FVBxB6 KO > WT at 80 dB; KO < WT at 100, 110, and
120 dB
[83]
FVBxB6 KO = WT [83]
Prepulse inhibition B6 KO > WT [73]
B6 KO > WT at 67 dB (2 dB above background
noise)
[107]
FVB KO > WT [110]
Audiogenic seizures (AS) FVB
B6 and FVBxB6
KO after long loud sound and after age 10 weeks
KO >> WT (143 ± 5 days)
KO >> WT (45 days and under)
KO display AS, WT do not (21 days)
[110]
[115]
[108]
[83]
FVB KO >> WT (30 days) [83]
Hot plate and tail-flick test FVB KO = WT [100]
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1171
mice enter a tube at opposite sides, meeting in the center, generally, one will push back the other and
hence be called dominant. The number of matches won by KO mice appeared to be dependent on the
familiarity of the opponent animal. Familiarity of the environment also has an effect on social
interactions; KO and WT spent as much time at the interface of two compartments with an unfamiliar
mouse in an unfamiliar cage, but they displayed a different pattern of social exploration when put in a
familiar cage[94].
Social interaction tests conducted by Spencer et al.[94] revealed that KO mice showed increased
active social behaviors when confronted with a WT or KO animal, increased receptive social behaviors
when opposed to a WT, and decreased receptive social behaviors when confronted with KO peers. In the
social interaction test conducted by Mineur et al.[95] using C3H ovariectomized females as stimulus
mice, KO displayed decreased social behavior in comparison to WT. A partition test (noncontact version
of the social interaction test) revealed no difference between KO and WT[94]. Despite some divergent
results most probably due to procedural differences, both groups concluded that social behavior is
abnormal in KO compared to WT.
A second group of core symptoms of autism concerns repetitive and stereotypic behaviors, resistance
to change, and restricted activities. To date, perseverance is the only aspect that has been investigated,
mostly on a B6 genetic background. It has been studied by the rate of extinction following training to
swim to a platform in various types of water mazes. Three of the studies found that Fmr1 KO mice had
significantly longer latencies to reach the changed position of a platform after learning an initial
position[82,89,96], whereas two other studies did not find any differences with WT[97,98]. Van Dam and
colleagues[98] used a cross-shaped water maze and found that although escape latencies were similar to
WT, Fmr1 KO mice made significantly less correct trials. These results seem to indicate that KO animals
are less flexible than WT and tend to persist in a once learned habit longer.
Regarding the variable symptoms of autism, most tests conducted on Fmr1 KO mice concerned the
murine equivalents of anxiety, mental retardation, hyperactivity, and idiosyncratic responses to sensory
stimuli (Table 2). Some features were found to be altered, but some showed no differences. Anxiety is
very often observed in autistic people and is linked to the impairment in anticipation that is thought to be
the origin of ritualistic behaviors[3]. This feature could also possibly be due to an alteration of amygdala
function[99]. An amygdala defect seems indeed to be present in Fmr1 KO mice as indicated by a trace
fear conditioning deficit[100] and altered social interactions. Most classical anxiety tests did not show any
differences between KO and WT[98,100,101,102], however, or KO were found to be even less anxious
than WT[82,91,94,101]. Abnormalities in corticosterone levels in response to restrain stress have
nevertheless been shown[103,104], resulting in altered negative feedback regulation of the glucocorticoid
response. In consequence, Fmr1 KO mice present a delayed response to stress and are also slower to
return to baseline[104]. FMRP binds to the glucocorticoid receptors and their expression was reduced in
the dendritic region of the Fmr1 KO mouse hippocampus[105]. It has indeed been reported that FXS
patients have a deregulated adrenopituitary axis[106].
Some studies on learning capacities indicated a deficit of KO mice in spatial learning tasks compared
to WT mice[82,83,98,102] while others did not report any deficit[83,91,97,101]. Deficits were found in
trace fear conditioning and were linked to LTP deficits in the lateral amygdala and cingulate cortex[100].
Similar deficits were found in Fmr1 KO on a mixed 129/FVB hybrid genetic background[102], which
were investigated in only this one study.
Motor abilities and aggression have been reported to be normal[91,101], but this may need further
exploration. Hyperactivity, however, seems to be the most consistent behavioral feature of Fmr1 KO mice
on a B6 genetic background[82,91,94,101]
although Nielsen et al.[107] reported no differences after a 5-
min observation in the open field. Hyperactivity in Fmr1 KO on a FVB/N background is still
controversial as they were reported not to be different from control mice[100] (as was the case in KO on
an FVBxB6 hybrid background[107]), but were significantly increased when test durations were longer
than 18 min[108].
Although no difference was found between KO and WT in nociception in response to heat, most other
responses to sensory stimuli were found to be altered in KO[100]. Koekkoek et al.[109] reported that
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1172
conditioned eye blink reflex was altered in a Purkinje cell specific Fmr1 KO on a B6 background.
Auditory startle response also seems to be FMRP dependent; although KO on both FVB and B6
backgrounds displayed opposite responses, they were both significantly different from WT[73,101,107].
Finally, Fmr1 KO mice on both genetic backgrounds were radically more prone to audiogenic seizures
than their WT homologues[83,110].
CONCLUSIONS
The Fmr1 KO mouse model has been studied for several behavioral and physiological features relevant to
autism and appears to display most expected symptoms. Although mixed results have been obtained for a
few behavioral features, other autism-specific features are undoubtedly impaired. Most results up till now
have been obtained with KO animals on the B6 background. It should be noted that in spite of the
relatively scarce data, it is clear that FVB mice also are affected by the KO mutation of Fmr1, but present
a specific behavioral profile different from the one displayed by B6 KOs. In particular, the Fmr1 KO
mutation was shown to have opposite effects on the sizes of the hippocampal intra- and infrapyramidal
mossy fiber (IIPMF) terminal fields, depending on whether the mutation was expressed on a B6 or FVB
background[90,91]. These IIPMF seem to be implicated in several behaviors[111,112]. Thus, it should be
interesting to carry out more systematic studies in both the B6 and FVB backgrounds. This might render a
plastic and reliable model for autism that takes into account the variability of the disorder in humans.
Despite the foregoing, it is clear that much work remains to be done before Fmr1 KO mice can be
validated as a model for autism. In particular, social communication and cognitive rigidity have hardly
been investigated yet. Several variable features of autism, such as sleep disturbance, brain overgrowth,
developmental delays, and stereotypies, also need more detailed investigation.
In conclusion, the etiology of autism remains unknown and the limitations of research in humans
make it necessary to develop animal models for this disorder. These models must fit construct, face, and
predictive validity criteria. Several possible models exist, but few of them have been extensively studied
as yet. The current short review shows that not only does the Fragile X Syndrome have a symptomatology
resembling autism to a very large extent and that the validated genetic mouse model that is available for
this disorder, the Fmr1 KO mouse also shows much promise as a possible model for autism.
ACKNOWLEDGMENTS
Supported by grants from the March of Dimes (12-FY05-1198), Conseil Régional d’Aquitaine, CNRS,
and the University of Bordeaux I to WEC.
REFERENCES
1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders IV-TR. 4th ed.
American Psychiatric Association Press, Washington, D.C.
2. Tsai, L.Y. (1999) Psychopharmacology in autism. Psychosom. Med. 61, 651–665.
3. Kanner, L. (1943) Autistic disturbances of affective contact. Nerv. Child. 2, 217–250.
4. Loesch, D.Z., Huggins, R.M., and Hagerman, R.J. (2004) Phenotypic variation and FMRP levels in fragile X. Ment.
Retard. Dev. Disabil. Res. Rev. 10, 31–41.
5. Baird, G., Charman, T., Baron-Cohen, S., Cox, A., Swettenham, J., Wheelwright, S., and Drew, A. (2000) A
screening instrument for autism at 18 months of age: a 6-year follow-up study. J. Am. Acad. Child Adolesc.
Psychiatry 39, 694–702.
6. Chakrabarti, S. and Fombonne, E. (2001) Pervasive developmental disorders in preschool children. JAMA 285, 3093–
3099.
7. Bertrand, J., Mars, A., Boyle, C., Bove, F., Yeargin-Allsopp, M., and Decoufle, P. (2001) Prevalence of autism in a
United States population: the Brick Township, New Jersey, investigation. Pediatrics 108, 1155–1161.
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1173
8. Yeargin-Allsopp, M., Rice, C., Karapurkar, T., Doernberg, N., Boyle, C., and Murphy, C. (2003) Prevalence of
autism in a US metropolitan area. JAMA 289, 49–55.
9. Fombonne, E. (2003) The prevalence of autism. JAMA 289, 87–89.
10. Fombonne, E. (1999) The epidemiology of autism: a review. Psychol. Med. 29, 769–786.
11. Baron-Cohen, S., Ring, H.A., Bullmore, E.T., Wheelwright, S., Ashwin, C., and Williams, S.C. (2000) The amygdala
theory of autism. Neurosci. Biobehav. Rev. 24, 355–364.
12. Blair, R.J. (2005) Responding to the emotions of others: dissociating forms of empathy through the study of typical
and psychiatric populations. Conscious Cogn. 14, 698–718.
13. Militerni, R., Bravaccio, C., Falco, C., Fico, C., and Palermo, M.T. (2002) Repetitive behaviors in autistic disorder.
Eur. Child Adolesc. Psychiatry 11, 210–218.
14. Bryson, S.E. and Smith, I.M. (1998) Epidemiology of autism: prevalence, associated characteristics, and implications
for research and service delivery. Ment. Retard. Dev. Disabil. Res. Rev. 4, 97–103.
15. Stahlberg, O., Soderstrom, H., Rastam, M., and Gillberg, C. (2004) Bipolar disorder, schizophrenia, and other
psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. J. Neural Transm. 111,
891–902.
16. Dominick, K.C., Davis, N.O., Lainhart, J., Tager-Flusberg, H., and Folstein, S. (2006) Atypical behaviors in children
with autism and children with a history of language impairment. Res. Dev. Disabil., in press.
17. Ghaziuddin, M., Ghaziuddin, N., and Greden, J. (2002) Depression in persons with autism: implications for research
and clinical care. J. Autism Dev. Disord. 32, 299–306.
18. Polimeni, M.A., Richdale, A.L., and Francis, A.J. (2005) A survey of sleep problems in autism, Asperger's disorder
and typically developing children. J. Intellect. Disabil. Res. 49, 260–268.
19. Williams, P.G., Sears, L.L., and Allard, A. (2004) Sleep problems in children with autism. J. Sleep Res. 13, 265–268.
20. Perry, W., Minassian, A., Lopez, B., Maron, L., and Lincoln, A. (2006) Sensorimotor gating deficits in adults with
autism. Biol. Psychiatry, in press.
21. Tuchman, R. and Rapin, I. (2002) Epilepsy in autism. Lancet Neurol. 1, 352–358.
22. Bachevalier, J. and Loveland, K.A. (2006) The orbitofrontal-amygdala circuit and self-regulation of social-emotional
behavior in autism. Neurosci. Biobehav. Rev. 30, 97–117.
23. Nayate, A., Bradshaw, J.L., and Rinehart, N.J. (2005) Autism and Asperger's disorder: are they movement disorders
involving the cerebellum and/or basal ganglia? Brain Res. Bull. 67, 327–334.
24. Hardan, A.Y., Minshew, N.J., and Keshavan, M.S. (2000) Corpus callosum size in autism. Neurology 55, 1033–1036.
25. Elia, M., Ferri, R., Musumeci, S.A., Panerai, S., Bottitta, M., and Scuderi, C. (2000) Clinical correlates of brain
morphometric features of subjects with low-functioning autistic disorder. J. Child Neurol. 15, 504–508.
26. Egaas, B., Courchesne, E., and Saitoh, O. (1995) Reduced size of corpus callosum in autism. Arch. Neurol. 52, 794–
801.
27. Bailey, A., Rutter, M., Luthert, P., Dean, A., Janota, I., Montgomery, M., Lantos, P., and Harding, B. (1998) A
clinicopathological study of autism. Brain 121, 889–905.
28. Casanova, M.F., Buxhoeveden, D.P., Switala, A.E., and Roy, E. (2002) Minicolumnar pathology in autism.
Neurology 58, 428–432.
29. Bauman, M.L. and Kemper, T.L. (2005) Structural brain anatomy. In The Neurobiology of Autism. 2nd ed. Bauman,
M.L. and Kemper, T.L., Eds. John Hopkins University Press, Baltimore, MD. pp. 121–135.
30. Bauman, M.L. and Kemper, T.L. (2005) Neuroanatomic observations of the brain in autism: a review and future
directions. Int. J. Dev. Neurosci. 23, 183–187.
31. Raymond, G.V., Bauman, M.L., and Kemper, T.L. (1996) Hippocampus in autism: a Golgi analysis. Acta
Neuropathol. 91, 117–119.
32. Arin, D.M., Bauman, M.L., and Kemper, T.L. (1991) The distribution of Purkinje cell loss in the cerebellum in
autism. Neurology 41, 307.
33. Ritvo, E.R., Freeman, B.J., and Scheibel, A.B. (1986) Lower Purkinje cell counts in the cerebella of four autistic
subjects: initial findings of the UCLA-NSAC autopsy research report. Am. J. Psychiatry 143, 862–866.
34. Bauman, M.L. and Kemper, T.L. (1996) Observations on the Purkinje cells in the cerebellar vermis in autism. J.
Neuropathol. Exp. Neurol. 55, 613.
35. Bauman, M.L. and Kemper, T.L. (1997) Is autism a progressive process? Neurology 48.
36. Hazlett, H.C., Poe, M., Gerig, G., Smith, R.G., Provenzale, J., Ross, A., Gilmore, J., and Piven, J. (2005) Magnetic
resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch. Gen.
Psychiatry 62, 1366–1376.
37. Libbey, J.E., Sweeten, T.L., McMahon, W.M., and Fujinami, R.S. (2005) Autistic disorder and viral infections. J.
Neurovirol. 11, 1–10.
38. Cohly, H.H. and Panja, A. (2005) Immunological findings in autism. Int. Rev. Neurobiol. 71, 317–341.
39. Arndt, T.L., Stodgell, C.J., and Rodier, P.M. (2005) The teratology of autism. Int. J. Dev. Neurosci. 23, 189–199.
40. Bartlett, C.W., Gharani, N., Millonig, J.H., and Brzustowicz, L.M. (2005) Three autism candidate genes: a synthesis
of human genetic analysis with other disciplines. Int. J. Dev. Neurosci. 23, 221–234.
41. Wassink, T., Brzustowicz, L., Bartlett, C.W., and Szatmari, P. (2004) The search for autism disease genes. Ment.
Retard. Dev Disabil. Res. Rev. 10, 272–283.
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1174
42. Mason-Brothers, A., Ritvo, E.R., Pingree, C., Petersen, P.B., Jenson, W.R., McMahon, W.M., Freeman, B.J., Jorde,
L.B., Spencer, M.J., Mo, A., et al. (1990) The UCLA-University of Utah epidemiologic survey of autism: prenatal,
perinatal, and postnatal factors. Pediatrics 86, 514–519.
43. Ritvo, E.R., Mason-Brothers, A., Freeman, B.J., Pingree, C., Jenson, W.R., McMahon, W.M., Petersen, P.B., Jorde,
L.B., Mo, A., and Ritvo, A. (1990) The UCLA-University of Utah epidemiologic survey of autism: the etiologic role
of rare diseases. Am. J. Psychiatry 147, 1614–1621.
44. Andres, C. (2002) Molecular genetics and animal models in autistic disorder. Brain Res. Bull. 57, 109–119.
45. Nicolson, R. and Szatmari, P. (2003) Genetic and neurodevelopmental influences in autistic disorder. Can. J.
Psychiatry 48, 526–537.
46. Weidmer-Mikhail, E., Sheldon, S., and Ghaziuddin, M. (1998) Chromosomes in autism and related pervasive
developmental disorders: a cytogenetic study. J. Intellect Disabil. Res. 42(Pt 1), 8–12.
47. Konstantareas, M.M. and Homatidis, S. (1999) Chromosomal abnormalities in a series of children with autistic
disorder. J. Autism Dev. Disord. 29, 275–285.
48. Lauritsen, M., Mors, O., Mortensen, P.B., and Ewald, H. (1999) Infantile autism and associated autosomal
chromosome abnormalities: a register-based study and a literature survey. J. Child Psychol. Psychiatry 40, 335–345.
49. Cohen, D., Pichard, N., Tordjman, S., Baumann, C., Burglen, L., Excoffier, E., Lazar, G., Mazet, P., Pinquier, C.,
Verloes, A., and Heron, D. (2005) Specific genetic disorders and autism: clinical contribution towards their
identification. J. Autism Dev. Disord. 35, 103–116.
50. Barton, M. and Volkmar, F. (1998) How commonly are known medical conditions associated with autism? J. Autism
Dev. Disord. 28, 273–278.
51. Chudley, A.E., Gutierrez, E., Jocelyn, L.J., and Chodirker, B.N. (1998) Outcomes of genetic evaluation in children
with pervasive developmental disorder. J. Dev. Behav. Pediatr. 19, 321–325.
52. Bailey, A., Le Couteur, A., Gottesman, I., Bolton, P., Simonoff, E., Yuzda, E., and Rutter, M. (1995) Autism as a
strongly genetic disorder: evidence from a British twin study. Psychol. Med. 25, 63–77.
53. Steffenburg, S., Gillberg, C., Hellgren, L., Andersson, L., Gillberg, I.C., Jakobsson, G., and Bohman, M. (1989) A
twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J. Child Psychol. Psychiatry 30, 405–416.
54. Ritvo, E.R., Freeman, B.J., Mason-Brothers, A., Mo, A., and Ritvo, A.M. (1985) Concordance for the syndrome of
autism in 40 pairs of afflicted twins. Am. J. Psychiatry 142, 74–77.
55. Bonora, E., Lamb, J.A., Barnby, G., Bailey, A.J., and Monaco, A.P. (2006) Genetic basis of autism. In Understanding
Autism: From Neuroscience to Treatment. Moldin. S.O. and Rubenstein, J.L.R., Eds. CRC Press, Boca Raton, FL. pp.
43–74.
56. Cook, E.H., Jr., Courchesne, R., Lord, C., Cox, N.J., Yan, S., Lincoln, A., Haas, R., Courchesne, E., and Leventhal,
B.L. (1997) Evidence of linkage between the serotonin transporter and autistic disorder. Mol. Psychiatry 2, 247–250.
57. Conroy, J., Meally, E., Kearney, G., Fitzgerald, M., Gill, M., and Gallagher, L. (2004) Serotonin transporter gene and
autism: a haplotype analysis in an Irish autistic population. Mol. Psychiatry 9, 587–593.
58. Belzung, C., Leman, S., Vourc'h, P., and Andres, C. (2005) Rodent models for autism: a critical review. Drug Discov,
Today 2, 93–101.
59. Seong, E., Saunders, T.L., Stewart, C.L., and Burmeister, M. (2004) To knockout in 129 or in C57BL/6: that is the
question. Trends Genet. 20, 59–62.
60. Teitelbaum, P. (2003) A proposed primate animal model of autism. Eur. Child Adolesc. Psychiatry 12, 48–49.
61. McKinney, W.T., Jr. and Bunney, W.E., Jr. (1969) Animal model of depression. I. Review of evidence: implications
for research. Arch. Gen. Psychiatry 21, 240–248.
62. McKinney, W.T., Gardner, R., Barlow, G.W., and McGuire, M.T. (1994) Conceptual basis of animal models in
psychiatry: a conference summary. Ethol. Sociobiol. 15, 369–382.
63. Gould, T.D. and Gottesman, I.I. (2006) Psychiatric endophenotypes and the development of valid animal models.
Genes Brain Behav. 5, 113–119.
64. Crawley, J.N. (2004) Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment. Retard. Dev.
Disabil. Res. Rev. 10, 248–258.
65. Hatton, D.D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D.B., Jr., Roberts, J., and Mirrett, P. (2006) Autistic
behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am. J. Med. Genet. A
140(17), 1804–1813.
66. Hagerman, R.J., Ono, M.Y., and Hagerman, P.J. (2005) Recent advances in fragile X: a model for autism and
neurodegeneration. Curr. Opin. Psychiatry
18, 490–496.
67. Rogers, S.J., Wehner, D.E., and Hagerman, R. (2001) The behavioral phenotype in fragile X: symptoms of autism in
very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J. Dev. Behav.
Pediatr. 22, 409–417.
68. Li, S.Y., Chen, Y.C., Lai, T.J., Hsu, C.Y., and Wang, Y.C. (1993) Molecular and cytogenetic analyses of autism in
Taiwan. Hum. Genet. 92, 441–445.
69. Fombonne, E., Du Mazaubrun, C., Cans, C., and Grandjean, H. (1997) Autism and associated medical disorders in a
French epidemiological survey. J. Am. Acad. Child Adolesc. Psychiatry 36, 1561–1569.
70. Bregman, J.D., Leckman, J.F., and Ort, S.I. (1988) Fragile X syndrome: genetic predisposition to psychopathology. J.
Autism Dev. Disord. 18, 343–354.
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1175
71. Gould, E.L., Loesch, D.Z., Martin, M.J., Hagerman, R.J., Armstrong, S.M., and Huggins, R.M. (2000) Melatonin
profiles and sleep characteristics in boys with fragile X syndrome: a preliminary study. Am. J. Hum. Genet. 95, 307–
315.
72. Musumeci, S.A., Hagerman, R.J., Ferri, R., Bosco, P., Dalla Bernardina, B., Tassinari, C.A., De Sarro, G.B., and Elia,
M. (1999) Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 40, 1092–1099.
73. Frankland, P.W., Wang, Y., Rosner, B., Shimizu, T., Balleine, B.W., Dykens, E.M., Ornitz, E.M., and Silva, A.J.
(2004) Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice. Mol.
Psychiatry 9, 417–425.
74. Feinstein, C. and Reiss, A.L. (1998) Autism: the point of view from fragile X studies. J. Autism Dev. Disord. 28, 393–
405.
75. Verheij, C., Bakker, C.E., de Graaff, E., Keulemans, J., Willemsen, R., Verkerk, A.J., Galjaard, H., Reuser, A.J.,
Hoogeveen, A.T., and Oostra, B.A. (1993) Characterization and localization of the FMR-1 gene product associated
with fragile X syndrome. Nature 363, 722–724.
76. Eberhart, D.E., Malter, H.E., Feng, Y., and Warren, S.T. (1996) The fragile X mental retardation protein is a
ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet. 5, 1083–1091.
77. Antar, L.N., Dictenberg, J., Plociniak, M., Afroz, R., and Bassell, G.J. (2005) Localization of FMRP-associated
mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes
Brain Behav. 4, 350–359.
78. Darnell, J.C., Mostovetsky, O., and Darnell, R.B. (2005) FMRP RNA targets: identification and validation. Genes
Brain Behav. 4, 341–349.
79. Li, Z., Zhang, Y., Ku, L., Wilkinson, K.D., Warren, S.T., and Feng, Y. (2001) The fragile X mental retardation
protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29, 2276–2283.
80. Lu, R., Wang, H., Liang, Z., Ku, L., O'Donnell, W.T., Li, W., Warren, S.T., and Feng, Y. (2004) The fragile X protein
controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc.
Natl. Acad. Sci. U. S. A. 101, 15201–15206.
81. Stefani, G., Fraser, C.E., Darnell, J.C., and Darnell, R.B. (2004) Fragile X mental retardation protein is associated
with translating polyribosomes in neuronal cells. J. Neurosci. 24, 7272–7276.
82. The Dutch-Belgian Fragile X Consortium (1994)
Fmr1 knockout mice: a model to study fragile X mental retardation.
Cell 78, 23–33.
83. Yan, Q.J., Asafo-Adjei, P.K., Arnold, H.M., Brown, R.E., and Bauchwitz, R.P. (2004) A phenotypic and molecular
characterization of the fmr1-tm1Cgr fragile X mouse. Genes Brain Behav. 3, 337–359.
84. Nimchinsky, E.A., Oberlander, A.M., and Svoboda, K. (2001) Abnormal development of dendritic spines in FMR1
knock-out mice. J. Neurosci. 21, 5139–5146.
85. Comery, T.A., Harris, J.B., Willems, P.J., Oostra, B.A., Irwin, S.A., Weiler, I.J., and Greenough, W.T. (1997)
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc. Natl. Acad. Sci. U. S. A.
94, 5401–5404.
86. Rudelli, R.D., Brown, W.T., Wisniewski, K., Jenkins, E.C., Laure-Kamionowska, M., Connell, F., and Wisniewski,
H.M. (1985) Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol. (Berl.) 67, 289–295.
87. Irwin, S.A., Patel, B., Idupulapati, M., Harris, J.B., Crisostomo, R.A., Larsen, B.P., Kooy, F., Willems, P.J., Cras, P.,
Kozlowski, P.B., Swain, R.A., Weiler, I.J., and Greenough, W.T. (2001) Abnormal dendritic spine characteristics in
the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am. J. Med. Genet.
98, 161–167.
88. Hinton, V.J., Brown, W.T., Wisniewski, K., and Rudelli, R.D. (1991) Analysis of neocortex in three males with the
fragile X syndrome. Am. J. Med. Genet. 41, 289–294.
89. Kooy, R.F., D'Hooge, R., Reyniers, E., Bakker, C.E., Nagels, G., De Boulle, K., Storm, K., Clincke, G., De Deyn,
P.P., Oostra, B.A., and Willems, P.J. (1996) Transgenic mouse model for the fragile X syndrome. Am. J. Med. Genet.
64, 241–245.
90. Ivanco, T.L. and Greenough, W.T. (2002) Altered mossy fiber distributions in adult Fmr1 (FVB) knockout mice.
Hippocampus 12, 47–54.
91. Mineur, Y.S., Sluyter, F., de Wit, S., Oostra, B.A., and Crusio, W.E. (2002) Behavioral and neuroanatomical
characterization of the Fmr1 knockout mouse. Hippocampus 12, 39–46.
92. Toubas, P.L., Abla, K.A., Cao, W., Logan, L.G., and Seale, T.W. (1990) Latency to enter a mirrored chamber: a novel
behavioral assay for anxiolytic agents. Pharmacol. Biochem. Behav. 35, 121–126.
93. Gallup, G.G., Jr. (1968) Mirror-image stimulation. Psychol. Bull. 70
, 782–793.
94. Spencer, C.M., Alekseyenko, O., Serysheva, E., Yuva-Paylor, L.A., and Paylor, R. (2005) Altered anxiety-related and
social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 4, 420–430.
95. Mineur, Y.S., Huynh, L.X., and Crusio, W.E. (2006) Social behavior deficits in the Fmr1 mutant mouse. Behav.
Brain Res. 168, 172–175.
96. D'Hooge, R., Nagels, G., Franck, F., Bakker, C.E., Reyniers, E., Storm, K., Kooy, R.F., Oostra, B.A., Willems, P.J.,
and De Deyn, P.P. (1997) Mildly impaired water maze performance in male Fmr1 knockout mice. Neuroscience 76,
367–376.
97. Paradee, W., Melikian, H.E., Rasmussen, D.L., Kenneson, A., Conn, P.J., and Warren, S.T. (1999) Fragile X mouse:
Bernardet and Crusio: Autistic features of Fmr1 KO mice
TheScientificWorldJOURNAL (2006) 6, 1164–1176
1176
strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience 94, 185–
192.
98. Van Dam, D., D'Hooge, R., Hauben, E., Reyniers, E., Gantois, I., Bakker, C.E., Oostra, B.A., Kooy, R.F., and De
Deyn, P.P. (2000) Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1
knockout mice. Behav. Brain Res. 117, 127–136.
99. Amaral, D.G., Bauman, M.D., and Schumann, C.M. (2003) The amygdala and autism: implications from non-human
primate studies. Genes Brain Behav. 2, 295–302.
100. Zhao, M.G., Toyoda, H., Ko, S.W., Ding, H.K., Wu, L.J., and Zhuo, M. (2005) Deficits in trace fear memory and
long-term potentiation in a mouse model for fragile X syndrome. J. Neurosci. 25, 7385–7392.
101. Peier, A.M., McIlwain, K.L., Kenneson, A., Warren, S.T., Paylor, R., and Nelson, D.L. (2000) (Over)correction of
FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum. Mol. Genet. 9, 1145–1159.
102. Dobkin, C., Rabe, A., Dumas, R., El Idrissi, A., Haubenstock, H., and Brown, W.T. (2000) Fmr1 knockout mouse has
a distinctive strain-specific learning impairment. Neuroscience 100, 423–429.
103. Lauterborn, J.C. (2004) Stress induced changes in cortical and hypothalamic c-fos expression are altered in fragile X
mutant mice. Mol. Brain Res. 131, 101–109.
104. Markham, J.A., Beckel-Mitchener, A.C., Estrada, C.M., and Greenough, W.T. (2006) Corticosterone response to
acute stress in a mouse model of Fragile X syndrome. Psychoneuroendocrinology 31, 781–785.
105. Miyashiro, K.Y., Beckel-Mitchener, A., Purk, T.P., Becker, K.G., Barret, T., Liu, L., Carbonetto, S., Weiler, I.J.,
Greenough, W.T., and Eberwine, J. (2003) RNA cargoes associating with FMRP reveal deficits in cellular
functioning in Fmr1 null mice. Neuron 37, 417–431.
106. Hessl, D., Glaser, B., Dyer-Friedman, J., Blasey, C., Hastie, T., Gunnar, M., and Reiss, A.L. (2002) Cortisol and
behavior in fragile X syndrome. Psychoneuroendocrinology 27, 855–872.
107. Nielsen, D.M., Derber, W.J., McClellan, D.A., and Crnic, L.S. (2002) Alterations in the auditory startle response in
Fmr1 targeted mutant mouse models of fragile X syndrome. Brain Res. 927, 8–17.
108. Qin, M., Kang, J., and Smith, C.B. (2005) A null mutation for Fmr1 in female mice: effects on regional cerebral
metabolic rate for glucose and relationship to behavior. Neuroscience 135, 999–1009.
109. Koekkoek, S.K., Yamaguchi, K., Milojkovic, B.A., Dortland, B.R., Ruigrok, T.J., Maex, R., De Graaf, W., Smit,
A.E., VanderWerf, F., Bakker, C.E., Willemsen, R., Ikeda, T., Kakizawa, S., Onodera, K., Nelson, D.L., Mientjes, E.,
Joosten, M., De Schutter, E., Oostra, B.A., Ito, M., and De Zeeuw, C.I. (2005) Deletion of FMR1 in Purkinje cells
enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome.
Neuron 47, 339–352.
110. Chen, L. and Toth, M. (2001) Fragile X mice develop sensory hyperreactivity to auditory stimuli. Neuroscience 103,
1043–1050.
111. Crusio, W.E. (2001) Genetic dissection of mouse exploratory behaviour. Behav. Brain Res. 125, 127–132.
112. Crusio, W.E. and Schwegler, H. (2005) Learning spatial orientation tasks in the radial-maze and structural variation in
the hippocampus in inbred mice. Behav. Brain Funct. 1, 3.
113. Brennan, F.X., Albeck, D.S., and Paylor, R. (2006) Fmr1 knockout mice are impaired in a leverpress
escape/avoidance task. Genes Brain Behav. 5, 467–471.
114. Ventura, R., Pascucci, T., Puglisi-Allegra, S., Catania, M.V., and Musumeci, S.A. (2004) Object recognition
impairment in Fmr1 knockout mice is reversed by amphetamine: Involvement of dopamine in the medial prefrontal
cortex. Behav. Pharmacol. 15, 433–442.
115. Musumeci, S.A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G.B., Elia, M., Ferri, R., and Oostra, B.A. (2000)
Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41, 19–23.
This article should be cited as follows:
Bernardet, M. and Crusio, W.E. (2006) Fmr1 KO mice as a possible model of autistic features. TheScientificWorldJOURNAL 6,
1164–1176. DOI 10.1100/tsw.2006.220.
... The Fmr1-KO mouse line models instead FXS that is the most common monogenic cause of ASD. Hence through a top-down approach, this model may allow to identify the neurobiological mechanisms involved in ASD etiopathology (Bernardet & Crusio, 2006;Pietropaolo et al., 2011). ...
... These symptoms overlap with many of the behavioral deficits observed in ASD (Bailey et al., 1998;Bailey et al., 2001;Brock & Hatton, 2010;Rogers et al., 2001) and the two pathologies are intertwined at the molecular level (Darnell et al., 2011;Parikshak et al., 2013). Since all FXS males meet some aspects of the DSM criteria for ASD and approximately 50%-80% meet the full criteria (Roberts et al., 2007), increased research interest has been devoted to the common mechanisms underlying FXS and ASD pathologies, thus prompting an interest in using FXS mouse models, that is, the Fmr1-KO lines (Mientjes et al., 2006;The Dutch-Belgian Fragile X Consortium, 1994), to study ASD (Bernardet & Crusio, 2006;Oddi et al., 2013;Pietropaolo & Subashi, 2014). ...
Article
Full-text available
Mice and rats emit ultrasonic vocalizations (USVs), which may express their arousal and emotional states, to communicate with each other. There is continued scientific effort to better understand the functions of USVs as a central element of the rodent behavioral repertoire. However, studying USVs is not only important because of their ethological relevance, but also because they are widely applied as a behavioral readout in various fields of biomedical research. In mice and rats, a large number of experimental models of brain disorders exist and studying the emission of USVs in these models can provide valuable information about the health status of the animals and the effectiveness of possible interventions, both environmental and pharmacological. This review (i) provides an updated overview of the contexts, in which ultrasonic calling behavior of mice and rats has particularly high translational value, and gives (ii) some examples of novel approaches and tools used for the analysis of USVs in mice and rats, combining qualitative and quantitative methods. The relevance of age and sex differences as well as the importance of longitudinal evaluations of calling and non‐calling behavior is also discussed. Finally, the importance of assessing the communicative impact of USVs in the receiver, i.e., through playback studies, is highlighted.
... These results indicate that inhibition of proBDNF cleavage causes instable dendritic spines. Selective increase in the density of thin spines (or filopodia) has been observed in Fmr1 KO mice [47], a mouse model for Fragile X Syndrome [48][49][50][51]. Together, our data indicates that high level of proBDNF together with extremely low level of mBDNF leads to deficits in spine density and maturation. ...
Article
Full-text available
Autism Spectrum Disorders (ASD) comprise a range of early age-onset neurodevelopment disorders with genetic heterogeneity. Most ASD related genes are involved in synaptic function, which is regulated by mature brain-derived neurotrophic factor (mBDNF) and its precursor proBDNF in a diametrically opposite manner: proBDNF inhibits while mBDNF potentiates synapses. Here we generated a knock-in mouse line (BDNFmet/leu) in which the conversion of proBDNF to mBDNF is attenuated. Biochemical experiments revealed residual mBDNF but excessive proBDNF in the brain. Similar to other ASD mouse models, the BDNFmet/leu mice showed reduced dendritic arborization, altered spines, and impaired synaptic transmission and plasticity in the hippocampus. They also exhibited ASD-like phenotypes, including stereotypical behaviors and deficits in social interaction. Moreover, the plasma proBDNF/mBDNF ratio was significantly increased in ASD patients compared to normal children in a case-control study. Thus, deficits in proBDNF to mBDNF conversion in the brain may contribute to ASD-like behaviors, and plasma proBDNF/mBDNF ratio may be a potential biomarker for ASD.
... Sensory hypersensitivity is also consistently seen in the Fmr1 KO mouse model of FXS [39][40][41][42]. Notably, Fmr1 KO mice display abnormal responses to auditory stimuli similar to humans, providing a translational platform to study developmental profiles and neural mechanisms of sensory circuit pathophysiology [43]. ...
Article
Full-text available
Background Autism spectrum disorders (ASD) encompass a wide array of debilitating symptoms, including sensory dysfunction and delayed language development. Auditory temporal processing is crucial for speech perception and language development. Abnormal development of temporal processing may account for the language impairments associated with ASD. Very little is known about the development of temporal processing in any animal model of ASD. Methods In the current study, we quantify auditory temporal processing throughout development in the Fmr1 knock-out (KO) mouse model of Fragile X Syndrome (FXS), a leading genetic cause of intellectual disability and ASD-associated behaviors. Using epidural electrodes in awake and freely moving wildtype (WT) and KO mice, we recorded auditory event related potentials (ERP) and auditory temporal processing with a gap-in-noise auditory steady state response (gap-ASSR) paradigm. Mice were recorded at three different ages in a cross sectional design: postnatal (p)21, p30 and p60. Recordings were obtained from both auditory and frontal cortices. The gap-ASSR requires underlying neural generators to synchronize responses to gaps of different widths embedded in noise, providing an objective measure of temporal processing across genotypes and age groups. Results We present evidence that the frontal, but not auditory, cortex shows significant temporal processing deficits at p21 and p30, with poor ability to phase lock to rapid gaps in noise. Temporal processing was similar in both genotypes in adult mice. ERP amplitudes were larger in Fmr1 KO mice in both auditory and frontal cortex, consistent with ERP data in humans with FXS. Conclusions These data indicate cortical region-specific delays in temporal processing development in Fmr1 KO mice. Developmental delays in the ability of frontal cortex to follow rapid changes in sounds may shape language delays in FXS, and more broadly in ASD.
... Fmr1 knockout (KO) mice are the best characterized model to study fragile X syndrome. This model also shows promising behavioural and physiological features to be used as a validated model for ASD (7). SH3 and multiple ankyrin repeat domain 3 (SHANK3) is a key post-synaptic scaffolding protein, whose disruption is associated with the development of Phelan-McDermid Syndrome. ...
Article
Full-text available
Autism spectrum disorder (ASD) comprises a wide range of neurodevelopment conditions primarily characterized by impaired social interaction and repetitive behavior, accompanied by a variable degree of neuropsychiatric characteristics. Synaptic dysfunction is undertaken as one of the key underlying mechanisms in understanding the pathophysiology of ASD. The excitatory/inhibitory (E/I) hypothesis is one of the most widely held theories for its pathogenesis. Shifts in E/I balance have been proven in several ASD models. In this study, we investigated three mouse lines recapitulating both idiopathic (the BTBR strain) and genetic (Fmr1 and Shank3 mutants) forms of ASD at late infancy and early adulthood. Using receptor autoradiography for ionotropic excitatory (AMPA and NMDA) and inhibitory (GABAA) receptors, we mapped the receptor binding densities in brain regions known to be associated with ASD such as prefrontal cortex, dorsal and ventral striatum, dorsal hippocampus, and cerebellum. The individual mouse lines investigated show specific alterations in excitatory ionotropic receptor density, which might be accounted as specific hallmark of each individual line. Across all the models investigated, we found an increased binding density to GABAA receptors at adulthood in the dorsal hippocampus. Interestingly, reduction in the GABAA receptor binding density was observed in the cerebellum. Altogether, our findings suggest that E/I disbalance individually affects several brain regions in ASD mouse models and that alterations in GABAergic transmission might be accounted as unifying factor.
... To study FraX, mice with global deletion of the FMR1 gene (Fmr1 −/− mice) have been developed, which mimic the human condition that results from more than 200 trinucleotide repeats, 5,6 and are widely used to understand the basis of FraX. These FMR1deficient mice, similar to humans with FraX, exhibit craniofacial abnormalities. ...
Article
Full-text available
Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene mutations lead to fragile X syndrome, cognitive disorders, and, in some individuals, scoliosis and craniofacial abnormalities. Four-month-old (mo) male mice with deletion of the FMR1 gene exhibit a mild increase in cortical and cancellous femoral bone mass. However, consequences of absence of FMR1 in bone of young/aged male/female mice and the cellular basis of the skeletal phenotype remain unknown. We found that absence of FMR1 results in improved bone properties with higher bone mineral density in both sexes and in 2- and 9-mo mice. The cancellous bone mass is higher only in females, whereas, cortical bone mass is higher in 2- and 9-mo males, but higher in 2- and lower in 9-mo female FMR1-knockout mice. Furthermore, male bones show higher biomechanical properties at 2mo, and females at both ages. Absence of FMR1 increases osteoblast/mineralization/bone formation and osteocyte dendricity/gene expression in vivo/ex vivo/in vitro, without affecting osteoclasts in vivo/ex vivo. Thus, FMR1 is a novel osteoblast/osteocyte differentiation inhibitor, and its absence leads to age-, site- and sex-dependent higher bone mass/strength.
... Vortioxetine has a receptor-binding profile particularly interesting for persons with ASD and cognitive issues. A dysfunction of the glutamatergic system and 5-HT7 receptors has been supported by some studies addressing behavioral flexibility and repetitive behavior in animal model of ASD [481,482]. Nevertheless, clinical data to date are lacking [483]. ...
Article
Unlabelled: AUTISM: spectrum disorders (ASD) often remain undiagnosed until adulthood. The aim of this study is to report differential diagnoses (DDX) and comorbidities of adults without intellectual impairment suspected of having an ASD and to test the self-assessment questionnaire Autism Quotient (AQ) for its suitability for screening. Methods: DDX and comorbidities were recorded with standardized scales in an autism outpatient clinic in 106 individuals. The AQ was tested against the expert judgment of an interdisciplinary case conference using ROC analysis. Results: Affective disorders were common in both groups (48%); other DDX were phobias (33%) and personality disorders (22%). The AQ showed an AUC of 0,527 with sensitivity/specificity of 70%/35%. Conclusions: Adults suspected of having autism are highly burdened by DDX and comorbidities. An interdisciplinary diagnostic procedure based on standardized scales is useful, whereas the AQ hardly differentiates between persons with and without ASD.
Article
Fragile X syndrome (FXS) is the most common inherited intellectual disability, caused by a lack of the fragile X mental retardation protein (FMRP). Individuals with neurodevelopmental disorders frequently experience gastrointestinal problems that are primarily linked to gut microbial dysbiosis, inflammation, and increased intestinal permeability. Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) are non-pharmacological agents that exert potential therapeutic effects against neurological disorders. However, it is unclear whether omega-3 PUFAs improve autistic behaviors in fragile X syndrome (FXS) by altering the gut microbial composition. Here, we describe gastrointestinal problems in Fmr1 knockout (KO) mice. FMRP deficiency causes intestinal homeostasis dysfunction in mice. Fish oil (FO) as a source of omega-3 PUFAs reduces intestinal inflammation but increases the mRNA and protein levels of TJP3 in the colon of juvenile Fmr1 KO mice. Fecal microbiota transplantation from FO-fed Fmr1 KO mice increased the gut abundance of Akkermansia and Gordonibacter in recipient Fmr1 KO mice and improved gut homeostasis and autistic behaviors. Our findings demonstrate that omega-3 PUFAs improve autistic behaviors and gut homeostasis in FMRP-deficient mice by suppressing gut microbiota dysbiosis, thereby presenting a novel therapeutic approach for juvenile FXS treatment.
Article
Fragile X syndrome is an X-linked form of mental retardation including, among others, symptoms such as stereotypic behaviour, hyperactivity, hyperarousal, and cognitive deficits. We hypothesized that hyperactivity and/or compromised attentional, cognitive functions may lead to impaired performance in cognitive tasks in Fmr1 knockout mice, the most widely used animal model of fragile X syndrome, and suggested that psychostimulant treatment may improve performance by acting on one or both components. Since hyperactivity and cognitive functions have been suggested to depend on striatal and prefrontal cortex dopaminergic dysfunction, we assessed whether amphetamine produced beneficial, positive effects by acting on dopaminergic corticostriatal systems. Our results show that Fmr1 knockout mice are not able to discriminate between a familiar object and a novel one in the object recognition test, thus showing a clear-cut cognitive impairment that, to date, has been difficult to demonstrate in other cognitive tasks. Amphetamine improved performance of Fmr1 knockout mice, leading to enhanced ability to discriminate novel versus familiar objects, without significantly affecting locomotor activity. In agreement with behavioural data, amphetamine produced a greater increase in dopamine release in the prefrontal cortex of Fmr1 knockout compared with the wild-type mice, while a weak striatal dopaminergic response was observed in Fmr1 knockout mice. Our data support the view that the psychostimulant ameliorates performance in Fmr1 knockout mice by improving merely cognitive functions through its action on prefrontal cortical dopamine, irrespective of its action on motor hyperactivity. These results indicate that prefrontal cortical dopamine plays a major role in cognitive impairments characterizing Fmr1 knockout mice, thus pointing to an important aetiological factor in the fragile X syndrome.
Article
Autism is a neurobiological disorder. The core clinical features of autism include impairment in social interaction, impairments in verbal and nonverbal communication, and restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. Autism often has coexisting neuropsychiatric disorders, including seizure disorders, attention deficit hyperactivity disorder, affective disorders, anxiety disorder, obsessive-compulsive disorder, and Tourette disorder. No etiology-based treatment modality has been developed to cure individuals with autism. However, comprehensive intervention, including parental counseling, behavior modification, special education in a highly structured environment, sensory integration training, speech therapy, social skill training, and medication, has demonstrated significant treatment effects in many individuals with autism. Findings from preliminary studies of major neurotransmitters and other neurochemical agents strongly suggest that neurochemical factors play a major role in autism. The findings also provide the rationale for psychopharmacotherapy in individuals with autism. This article reviews studies of neurochemical systems and related psychopharmacological research in autism and related neuropsychiatric disorders. Clinical indications for pharmacotherapy are described, and uses of various medications are suggested. This article also discusses new avenues of investigation that may lead to the development of more effective medication treatments in persons with autism.
Article
It has been more than 60 years since Kanner (1943) first described autism in a series of 11 children who presented with a cluster of symptoms that included poor social relatedness, obsessive and stereotypic behaviors, and disordered language. In DSM-III (American Psychiatric Association, 1980), the term "pervasive developmental disorder" (PDD) was introduced to describe more mildly affected individuals with autistic-like features associated with disordered or distorted behavioral and cognitive development. Although initially believed to be distinctly different disorders, there is now a growing consensus that PDD and autism are part of a continuum (Allen et al., 1988), and the term "autism spectrum disorder" (ASD) has come into common usage. © 2005 by The The Johns Hopkins University Press. All rights reserved.
Conference Paper
Autism is a neurobiological disorder. The core clinical features of autism include impairment in social interaction, impairments in verbal and nonverbal communication, and restricted, repetitive, and stereotyped patterns of behavior, interests, and activities. Autism often has coexisting neuropsychiatric disorders, including seizure disorders, attention deficit hyperactivity disorder, affective disorders, anxiety disorder, obsessive-compulsive disorder, and Tourette disorder. No etiology-based treatment modality has been developed to cure individuals with autism. However, comprehensive intervention, including parental counseling, behavior modification, special education in a highly structured environment, sensory integration training, speech therapy, social skill training, and medication, has demonstrated significant treatment effects in many individuals with autism. Findings from preliminary studies of major neurotransmitters and other neurochemical agents strongly suggest that neurochemical factors play a major role in autism. The findings also provide the rationale for psychopharmacotherapy in individuals with autism. This article reviews studies of neurochemical systems and related psychopharmacological research in autism and related neuropsychiatric disorders. Clinical indications for pharmacotherapy are described, and uses of various medications are suggested. This article also discusses new avenues of investigation that may lead to the development of more effective medication treatments in persons with autism.
Article
Male patients with fragile X syndrome lack FMRl pro-tein due to silencing of the FMRl gene by amplification of a CGG repeat and subsequent methylation of the promoter region. The absence of FMRl protein leads to mental retardation, aberrant behavior, and macroor-chidism. Hardly anything is known about the physiologi-cal function of FMR1 and the pathological mechanisms leading to these symptoms. Therefore, we designed a knockout model for the fragile X syndrome in mice. The knockout mice lack normal Fmrl protein and show mac-roorchidism, learning deficits, and hyperactivity. Consequently, this knockout mouse may serve as a valuable tool in the elucidation of the physiological role of FMR7 and the mechanisms involved in macroorchidism, abnormal behavior, and mental retardation.
Article
Future progress in selected areas of psychiatric research will depend upon use of animal models. The incorporation of such models into clinical psychiatry needs to be done carefully and in a way not only consonant with descriptive psychiatry and cellular-molecular biology, but also with evolutionary biology and related fields. This report summarizes critical concepts of evolutionary biology that provide a framework for relating animal modeling research to clinical issues.